Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Scotland says yes to Eliquis and Incivo but declines Ozurdex and Xgeva

This article was originally published in Scrip

Executive Summary

Scotland's health technology appraisal body, the Scottish Medicines Consortium (SMC) has approved Vertex/Janssen-Cilag's hepatitis C drug Incivo (telaprevir) and Bristol-Myers Squibb/Pfizer's Eliquis (apixaban) for preventing venous thromboembolism for use on the NHS. However, it turned down Allergan's Ozurdex (dexamethasone) for macular oedema following central or branch retinal vein occlusion (C/BRVO)and Amgen's Xgeva (denosumab) for preventing skeletal related events in adults with bone metastases from solid tumours.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC015548

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel